Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?
Breast cancer
Cardiotoxicity
Cardio‐oncology
HER2
Trastuzumab
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
19
03
2019
accepted:
06
06
2019
pubmed:
19
7
2019
medline:
1
8
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Trastuzumab is an effective treatment for HER2-positive breast cancer. Current guidelines recommend withholding trastuzumab in patients experiencing a significant asymptomatic decline in left ventricular function. In this commentary, we discuss the survival benefits afforded by trastuzumab juxtaposed against the risk of trastuzumab-mediated cardiotoxicity. It is not known whether the net benefit of continuing trastuzumab in the setting of mild cardiotoxicity outweighs the associated risks. We describe a potential approach undertaken by our group, and others, and call for a randomized trial.
Identifiants
pubmed: 31315962
pii: theoncologist.2019-0263
doi: 10.1634/theoncologist.2019-0263
pmc: PMC6853116
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1405-1409Informations de copyright
© AlphaMed Press 2019.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
J Clin Oncol. 2005 May 1;23(13):2900-2
pubmed: 15860848
N Engl J Med. 1992 Sep 3;327(10):685-91
pubmed: 1463530
N Engl J Med. 1991 Aug 1;325(5):303-10
pubmed: 2057035
J Am Coll Cardiol. 2013 Jan 8;61(1):77-84
pubmed: 23199515
J Biol Chem. 1998 Apr 24;273(17):10261-9
pubmed: 9553078
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
J Clin Oncol. 2005 Nov 1;23(31):7820-6
pubmed: 16258084
Breast. 2018 Feb;37:64-71
pubmed: 29101824
Oncologist. 2015 Oct;20(10):1105-10
pubmed: 26240135
JAMA Oncol. 2016 Jan;2(1):29-36
pubmed: 26539793
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
JAMA Oncol. 2018 Sep 1;4(9):1199-1206
pubmed: 29852043
Eur J Cancer. 2007 Sep;43(14):2046-51
pubmed: 17719768
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
J Clin Oncol. 2007 Sep 1;25(25):3859-65
pubmed: 17646669
J Clin Oncol. 2016 Apr 1;34(10):1030-3
pubmed: 26834055
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243
pubmed: 22513938
J Am Coll Cardiol. 2019 Aug 6;74(5):683-698
pubmed: 31370961
Oncologist. 2017 May;22(5):518-525
pubmed: 28314836
Ann Oncol. 2018 Dec 1;29(12):2328-2333
pubmed: 30219886
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Eur J Cancer. 2013 Sep;49(13):2900-9
pubmed: 23706982
Cancer Treat Rev. 2017 Nov;60:18-23
pubmed: 28863313
JAMA. 2002 Feb 20;287(7):883-9
pubmed: 11851582
Curr Oncol. 2008 Jan;15(1):24-35
pubmed: 18317582
J Clin Oncol. 2010 Jul 20;28(21):3429-36
pubmed: 20530277
Lancet. 2000 May 6;355(9215):1575-81
pubmed: 10821360
Breast Cancer Res Treat. 2019 Jun;175(3):595-603
pubmed: 30852761
Curr Oncol. 2019 Aug;26(4):240-246
pubmed: 31548803